These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 27595250)

  • 1. [Characterisation of thromboembolic risk in a mexican population with non-valvular atrial fibrillation and its effect on anticoagulation (MAYA Study)].
    Vázquez-Acosta JA; Ramírez-Gutiérrez ÁE; Cerecedo-Rosendo MA; Olivera-Barrera FM; Tenorio-Sánchez SS; Nieto-Villarreal J; González-Borjas JM; Villanueva-Rodríguez E
    Gac Med Mex; 2016; 152(4):473-8. PubMed ID: 27595250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The predictive ability of the CHADS2 and CHA2DS2-VASc scores for bleeding risk in atrial fibrillation: the MAQI(2) experience.
    Barnes GD; Gu X; Haymart B; Kline-Rogers E; Almany S; Kozlowski J; Besley D; Krol GD; Froehlich JB; Kaatz S
    Thromb Res; 2014 Aug; 134(2):294-9. PubMed ID: 24929840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation.
    Roldán V; Marín F; Manzano-Fernández S; Gallego P; Vílchez JA; Valdés M; Vicente V; Lip GY
    J Am Coll Cardiol; 2013 Dec; 62(23):2199-204. PubMed ID: 24055744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stroke and bleeding risk co-distribution in real-world patients with atrial fibrillation: the Euro Heart Survey.
    Marcucci M; Lip GY; Nieuwlaat R; Pisters R; Crijns HJ; Iorio A
    Am J Med; 2014 Oct; 127(10):979-986.e2. PubMed ID: 24838192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence, main determinants, and early outcome of patients with atrial fibrillation hospitalized with ischemic stroke: evaluation of the value of risk assessment scores for predicting risk of stroke or major bleeding following anticoagulation therapy.
    Sadeghi R; Parsa Mahjoob M; Asadollahi M; Abbasi Z
    Acta Biomed; 2015 Sep; 86(2):162-9. PubMed ID: 26422431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the CHA
    Yao X; Gersh BJ; Sangaralingham LR; Kent DM; Shah ND; Abraham NS; Noseworthy PA
    Am J Cardiol; 2017 Nov; 120(9):1549-1556. PubMed ID: 28844514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of renal function deterioration on adverse events during anticoagulation therapy using non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.
    Miyamoto K; Aiba T; Arihiro S; Watanabe M; Kokubo Y; Ishibashi K; Hirose S; Wada M; Nakajima I; Okamura H; Noda T; Nagatsuka K; Noguchi T; Anzai T; Yasuda S; Ogawa H; Kamakura S; Shimizu W; Miyamoto Y; Toyoda K; Kusano K
    Heart Vessels; 2016 Aug; 31(8):1327-36. PubMed ID: 26276272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the CHADS2, CHA2DS2-VASc and HAS-BLED scores for the prediction of clinically relevant bleeding in anticoagulated patients with atrial fibrillation: the AMADEUS trial.
    Apostolakis S; Lane DA; Buller H; Lip GY
    Thromb Haemost; 2013 Nov; 110(5):1074-9. PubMed ID: 24048467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Usefulness of the CHA
    Jaakkola S; Kiviniemi TO; Nuotio I; Hartikainen J; Mustonen P; Palomäki A; Jaakkola J; Ylitalo A; Hartikainen P; Airaksinen KEJ
    Am J Cardiol; 2018 May; 121(10):1182-1186. PubMed ID: 29526276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of Adherence to Guideline-Directed Antithrombotic Therapy for Atrial Fibrillation at Hospital Discharge.
    Dupree L; DeLosSantos M; Smotherman C
    J Cardiovasc Pharmacol Ther; 2018 Nov; 23(6):502-508. PubMed ID: 29806486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How well does physician risk assessment predict stroke and bleeding in atrial fibrillation? Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF).
    Steinberg BA; Shrader P; Kim S; Thomas L; Fonarow GC; Ansell J; Kowey PR; Singer DE; Gersh BJ; Mahaffey KW; Peterson ED; Piccini JP;
    Am Heart J; 2016 Nov; 181():145-152. PubMed ID: 27823686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Joint use of cardio-embolic and bleeding risk scores in elderly patients with atrial fibrillation.
    Marcucci M; Nobili A; Tettamanti M; Iorio A; Pasina L; Djade CD; Franchi C; Marengoni A; Salerno F; Corrao S; Violi F; Mannucci PM;
    Eur J Intern Med; 2013 Dec; 24(8):800-6. PubMed ID: 24035703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A comparison of CAS risk model and CHA
    Deng JL; He L; Jiang C; Lai YW; Long DY; Sang CH; Jia CQ; Feng L; Li X; Ning M; Hu R; Dong JZ; Du X; Tang RB; Ma CS
    Zhonghua Xin Xue Guan Bing Za Zhi; 2022 Sep; 50(9):888-894. PubMed ID: 36096706
    [No Abstract]   [Full Text] [Related]  

  • 14. Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation.
    Fox KAA; Lucas JE; Pieper KS; Bassand JP; Camm AJ; Fitzmaurice DA; Goldhaber SZ; Goto S; Haas S; Hacke W; Kayani G; Oto A; Mantovani LG; Misselwitz F; Piccini JP; Turpie AGG; Verheugt FWA; Kakkar AK;
    BMJ Open; 2017 Dec; 7(12):e017157. PubMed ID: 29273652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meta-analysis of CHADS2 versus CHA2DS2-VASc for predicting stroke and thromboembolism in atrial fibrillation patients independent of anticoagulation.
    Zhu WG; Xiong QM; Hong K
    Tex Heart Inst J; 2015 Feb; 42(1):6-15. PubMed ID: 25873792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anticoagulant Therapy in Atrial Fibrillation for Stroke Prevention: Assessment of Agreement Between Clinicians' Decision and CHA2DS2-VASc and HAS-BLED Scores.
    Balaghi-Inalou M; Parsa SA; Gachkar L; Andalib S
    High Blood Press Cardiovasc Prev; 2018 Mar; 25(1):61-64. PubMed ID: 29076078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Warfarin therapy for atrial fibrillation in general practice--is bleeding risk underestimated?
    Bratland B; Hornnes MB
    Tidsskr Nor Laegeforen; 2014 Jan; 134(2):175-9. PubMed ID: 24477151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dynamic assessment of CHA
    Serna MJ; Rivera-Caravaca JM; López-Gálvez R; Soler-Espejo E; Lip GYH; Marín F; Roldán V
    Rev Esp Cardiol (Engl Ed); 2024 Oct; 77(10):835-842. PubMed ID: 38460882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Balancing bleeding and thrombotic risk with new oral anticoagulants in patients with atrial fibrillation.
    Overvad TF; Larsen TB; Albertsen IE; Rasmussen LH; Lip GY
    Expert Rev Cardiovasc Ther; 2013 Dec; 11(12):1619-29. PubMed ID: 24215192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bleeding risk assessment in patients with atrial fibrillation who are taking oral anticoagulants.
    Guo Y; Lip GY; Apostolakis S
    Hosp Pract (1995); 2013 Feb; 41(1):71-8. PubMed ID: 23466969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.